Literature DB >> 15927811

Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin.

Sonja Ständer1, Martin Schmelz, Dieter Metze, Thomas Luger, Roman Rukwied.   

Abstract

BACKGROUND: Cannabinoid receptors mediate the psychopharmacological action of marijuana and have been localized in the central and peripheral nervous system as well as on cells of the immune system.
OBJECTIVE: Up to now, two cannabinoid receptors (CB1 and CB2) have been cloned and recent studies on animal tissue gave evidence for the presence of cannabinoid receptors in the skin.
METHODS: In the present immunohistochemical investigation we determined the precise localization of CB1 and CB2 in sections of human skin and in one case of mastocytosis.
RESULTS: CB1 and CB2 immunoreactivity was observed in cutaneous nerve fiber bundles, mast cells, macrophages, epidermal keratinocytes, and the epithelial cells of hair follicles, sebocytes and eccrine sweat glands. In epidermal keratinocytes, hair follicle and sebaceous glands, CB1 and CB2 were distributed in a complementary fashion. Double-immunostaining with an anti-CGRP antibody suggested the presence of cannabinoid receptors on small afferent peptidergic nerves.
CONCLUSION: The abundant distribution of cannabinoid receptors on skin nerve fibers and mast cells provides implications for an anti-inflammatory, anti-nociceptive action of cannabinoid receptor agonists and suggests their putatively broad therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927811     DOI: 10.1016/j.jdermsci.2005.01.007

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  81 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

Review 2.  Inhibiting the breakdown of endogenous opioids and cannabinoids to alleviate pain.

Authors:  Bernard P Roques; Marie-Claude Fournié-Zaluski; Michel Wurm
Journal:  Nat Rev Drug Discov       Date:  2012-04       Impact factor: 84.694

3.  Differences in peripheral endocannabinoid modulation of scratching behavior in facial vs. spinally-innervated skin.

Authors:  Jessica Marie Spradley; Auva Davoodi; Leland Bruce Gee; Mirela Iodi Carstens; E Carstens
Journal:  Neuropharmacology       Date:  2012-06-06       Impact factor: 5.250

Review 4.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 5.  [Mechanisms in the development of pain. Key issue in the periphery].

Authors:  C Konrad; M Schmelz
Journal:  Internist (Berl)       Date:  2005-10       Impact factor: 0.743

6.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

7.  Distribution of bioactive lipid mediators in human skin.

Authors:  Alexandra C Kendall; Suzanne M Pilkington; Karen A Massey; Gary Sassano; Lesley E Rhodes; Anna Nicolaou
Journal:  J Invest Dermatol       Date:  2015-02-10       Impact factor: 8.551

8.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

Review 9.  The endocannabinoid system and pain.

Authors:  Josée Guindon; Andrea G Hohmann
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

Review 10.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.

Authors:  Tamás Bíró; Balázs I Tóth; György Haskó; Ralf Paus; Pál Pacher
Journal:  Trends Pharmacol Sci       Date:  2009-07-14       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.